CWRU researchers block cancer’s spread to body with novel technique

Summary: In a medical first, scientists at CWRU have inhibited metastasis – the spread of cancer cells to another part of the body. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

In a first of its kind victory, researchers from the Case Western Reserve University (CWRU) School of Medicine and six other institutions have inhibited the spread of cancer cells from one part of the body to another.

To accomplish this feat, the team relied on a novel epigenetic model of how cancer metastasizes. Epigenetics is the master program which turns genes on and off. The group included researchers from the National Cancer Institute (NCI) and the Cleveland Clinic. The researchers published their results in the journal Nature Medicine.

The team used novel epigenetic-centered techniques to halt the spread of bone cancer to the lungs of mice. The vast majority of deaths that come from bone cancer are due to the disease spreading to the lungs; a process referred to as metastasis. Most cases of bone cancer occur in young people, typically between the ages of 10 and 30. Teenagers are the most frequently affected age group. The outlook for patients with bone cancer, known as osteosarcoma, has not improved in more than 3 decades. There are no approved targeted anti-metastatic treatments for the disease in widespread clinical use.

Peter Scacheri, Ph.D., is the study’s senior author and professor of genetics and genome sciences at the CWRU School of Medicine. As Dr. Scacheri puts it,

“More than 90 percent of all cancer deaths are the result of tumor metastasis, not primary-site tumors,” adding, “While many of the genes responsible for metastasis have been identified, the mechanisms that control these genes are not well defined. Our findings demonstrate that altered gene-enhancer activity is fundamental to a cancer cell’s ability to metastasize.”

The CWRU School of Medicine focus on epigenetics represents a break with the mainstream view that genetic mutations are the primary driver of tumor metastases.  The epigenetic program is the master of our genetic code, in that it controls how genes are turned on or off.

Additionally, the team’s focus on the role of epigenetics in cancer also represents a departure from mainstream cancer research. Mainstream researchers are not so much interested in metastasis. Instead, they tend to focus on the early stages of the disease and are concerned with how tumors form and what distinguishes cancer cells from normal one. Moreover, most cancer drugs and treatments today are intended to kill primary tumors, not the cancer cells that have spread elsewhere.

Gene enhancers are short snippets of DNA that, when bound by specialized proteins called transcription factors, operate much like switches to activate genes. This process is essential for healthy development; For example, it is relied upon when the fertilized egg develops into the different cell types which make up the body. Each cell has tens of thousands of gene enhancers, exceeding the number of genes themselves. Not only do they switch the genes on and off they can act very much like a volume knob, gradually controlling the expression of a gene.  Even though all cells have the same DNA, the on and off settings determines a cell’s role  – a certain group of switch settings yield a heart cell, while another set produces lung tissue.

However, faulty enhancer regulation contributes to the growth of tumors and their subsequent spread. Moreover, different cancers are distinguishable by different enhancer patterns. The authors of the new study showed that the on-off switches of cancer cells that have metastasized are in different positions than in the cells of the source tumor.

James J. Morrow, Ph.D. is the study’s lead author and a medical student at CWRU School of Medicine. As Dr. Morrow says,

“Metastasis results from a complex set of traits acquired by tumor cells, distinct from those necessary for tumors to form in the first place,” adding “Unfortunately, searching for gene mutations that drive metastasis has not substantially improved outcomes for patients with metastatic disease. Five-year survival rates for cancer patients with regional or localized disease have significantly improved for many types of cancer. But with few exceptions, outcomes for patients with metastatic cancer have remained stagnant. It is well established that primary tumor formation is driven by a combination of genetic and epigenetic events. So, based on the knowledge that enhancers drive both normal cell development and tumor-formation, we hypothesized that they may play a similar role in the transition of cancer cells from one developmentally distinct tissue to another during metastatic progression.”

The CWRU-led team used epigenomic profiling experiments to identify bunched clusters of gene enhancers, called metastatic variant enhancer loci (Met-VELs). The scientists found Met-VELS near cancer genes in the lung metastases of patients with bone cancer, indicating they were essential to the metastatic process. Using lab mice, the researchers then showed that they could inhibit the growth of bone cancer cells in the lung using BET inhibitors. These inhibitors are currently being tested in clinical trials as anti-cancer drugs, and broadly inhibit Met-VELs in driving gene expression.

Second, the CWRU-led group demonstrated that they could diminish the metastatic capacity of bone cancer cells by blocking the expression of individual genes regulated by Met-VELs or the transcription factors driving that regulation. The team verified that a particular Met-VEL-linked gene, called Tissue Factor (F3), is essential for metastatic colonization. The researchers found that using antibodies to interrupt the signaling and blood clotting functions of F3 prevented metastasis. Additionally, the researchers showed that deleting a single Met-VEL regulating F3 expression using gene editing achieved a similar effect. As Dr. Scacheri puts it,

“Our experiments show that removing a single enhancer of the F3 gene in tumor cells virtually eliminates their ability to metastasize in mice,” adding “Collectively, our findings establish that enhancer elements endow tumor cells with metastatic capacity and that targeted inhibition of genes associated with enhancer alterations, or deleting altered enhancers themselves is sufficient to block metastatic colonization and proliferation. While our work focused on lung metastasis in osteosarcoma, the findings have implications for other types of metastatic cancer as well.”

Related Articles

• Stealth virus holds promise in cancer therapy. 
• CAR T cell therapy to treat lymphoma shows promise in cancer treatment.
• Team paves the way for immunotherapy to treat aggressive colon tumors.
• Novel cancer ‘vaccine’ eliminates tumors in mice.
• BioViva’s Liz Parrish updates the progress of gene therapy clinical trials on cancer.

Like this Article?

• Help us spread the word –  Share this article on social media. It only takes one click on any of the links on this page.
• Follow us on social media –  Google+ or Reddit
• Sign up for our email list – We use your email to notify you of new articles. We will not send you spam, and we will not share your email address. You can cancel at any time.
• Tell us what you think  – Scroll down to enter your comments below.

References

“Researchers inhibit cancer metastases via novel steps.” Case Western Reserve University.  February 12, 2018. Link to the press release in MedicalXpress.

James J Morrow et al., “Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.” Nature Medicine (2018). DOI: 10.1038/nm.4475. Link to article in Nature Medicine.

Disclaimer

Diagnosis, Treatment, and Advice:  This article is intended for informational and educational purposes only and is not a substitute for qualified, professional medical advice.  The opinions and information stated in this article should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. Consult a qualified and licensed physician for the diagnosis and treatment of any and all medical conditions. Experimental cancer treatments carry a much higher risk than FDA-approved ones. Dial 9-1-1, or an equivalent emergency hotline number, for all medical emergencies. As well, consult a licensed, qualified physician before changing your diet, supplement or exercise programs.
Photos, Endorsements, & External Links:  This article is not intended to endorse organizations, companies, or their products. Links to external websites, mention or depiction of company names or brands, are intended for illustration only and do not constitute endorsements.

Tags: Cancer, Nanodoc, Nanorobot